

09 May 2024

Biologic Medicines in Dermatology

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- **Adalimumab – Humira** - 43
- **Adalimumab Biosimilar** - 217
- **Apremilast** 12
- **Bimekizumab** - 13
- **Brodalumab** - <5
- **Certolizumab** - 8
- **Deucravacitinib** - <5
- **Dimethyl fumarate** - <5
- **Etanercept – Enbrel** - <5
- **Etanercept Biosimilar** - 7
- **Guselkumab** - 87
- **Infliximab – Remicade** - <5
- **Infliximab Biosimilar** - 9
- **Ixekizumab** - 60
- **Risankizumab** - 89
- **Secukinumab** - 40
- **Tildrakizumab** - 5
- **Ustekinumab** - 72

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- **Adalimumab – Humira** - 17
- **Adalimumab Biosimilar** - 25
- **Bimekizumab** - <5
- **Certolizumab** - <5
- **Infliximab – Remicade** - <5
- **Infliximab Biosimilar** - 6
- **Secukinumab** - <5
- **Ustekinumab** - <5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.